Dane Leone
Stock Analyst at Raymond James
(1.15)
# 3,760
Out of 5,014 analysts
69
Total ratings
33.96%
Success rate
-8.13%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $6.11 | +210.97% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.84 | +375.62% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $12.22 | +268.25% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $47.82 | -37.26% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $563.86 | +68.48% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.09 | +522.01% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $55.30 | -16.82% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $34.50 | +100.00% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $3.90 | +105.13% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $11.91 | +17.55% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $12.40 | +367.74% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $16.47 | +325.02% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.47 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $60.82 | +3.58% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $44.54 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.62 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $69.75 | -6.81% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $294.62 | -13.45% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $5.28 | +506.06% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $189.69 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $6.11
Upside: +210.97%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.84
Upside: +375.62%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $12.22
Upside: +268.25%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $47.82
Upside: -37.26%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $563.86
Upside: +68.48%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.09
Upside: +522.01%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $55.30
Upside: -16.82%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $34.50
Upside: +100.00%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $3.90
Upside: +105.13%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $11.91
Upside: +17.55%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $12.40
Upside: +367.74%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $16.47
Upside: +325.02%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $60.82
Upside: +3.58%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $44.54
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.62
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $69.75
Upside: -6.81%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $294.62
Upside: -13.45%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $5.28
Upside: +506.06%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $189.69
Upside: -